
AI-driven drug discovery platform helping pharma and biotech firms find and license therapeutic assets
Drug discovery company founded in 2021 by Sir Demis Hassabis, building predictive and generative AI models and its IsoDDE drug design engine; collaborates with MSD and has announced a Series C round.
Isomorphic Labs sets out to develop new medicines by pairing its own frontier AI with scientific research. It was founded in 2021 by Sir Demis Hassabis, and the company says the idea grew out of the AlphaFold work on predicting protein structures at Google DeepMind. Its name reflects a belief that biology and information science share a deep symmetry.
The company's central platform is the Isomorphic Labs Drug Design Engine, shortened to IsoDDE. It uses predictive and generative models to study biology, explore chemical space and work on hard design problems, and the company builds such models across several kinds of drug. It says its lead internal programmes are moving towards the clinic. AI researchers and engineers work alongside specialists in chemistry, biology, drug discovery and clinical development.
The site announces a strategic research collaboration with MSD and says the company has joined the Virtual Biology Initiative, which aims to build foundational data for AI models that predict and treat disease. It also announces a Series C investment round, without giving an amount or investors on its home page.
Hassabis is founder and chief executive, and Max Jaderberg is president. The leadership page also lists Miles Congreve as chief scientific officer, Sarah Korman as chief operating officer, Beverley Mallon as chief people and experience officer, Sarah Skerratt as chief research officer and Ben Wolf as chief medical officer. The scientific advisory board names Jennifer Doudna, Sir David MacMillan, Sir Paul Nurse, Sir Menelas Pangalos and Venki Ramakrishnan. Separate contact addresses are given for press, partnering and general enquiries.
Company: Isomorphic Labs Founded: 2021, by Sir Demis Hassabis Platform: Isomorphic Labs Drug Design Engine (IsoDDE) People: Sir Demis Hassabis (CEO), Max Jaderberg (president) Partnership: strategic research collaboration with MSD Website: https://www.isomorphiclabs.com
Summary written by TrustList from the business's own published information, Nov 2026.
An earned signal from verification, reviews, awards, transparency and engagement - the vendor can't buy it.
Updated 11/20/2026
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about Isomorphic Labs.
Similar listings buyers compare against this one.

AI-driven drug discovery platform helping pharma and biotech firms find and license therapeutic assets

AI and computer vision system that watches aircraft turnarounds to cut delays for airports and airlines
Enterprise AI agent platform for customer service, employee support and process automation

Voice AI agents that answer and make calls for contact centres, banks and insurers

Polish data labelling company supporting AI teams with visual, text, voice and medical data annotation

Enterprise AI company offering the GRACE platform for AI governance, security and model operations, plus data science expertise
Toronto software company using computer vision and edge AI to count vehicles, detect incidents and track movement in transport

AI-focused consultancy helping manufacturers plan production and apply AI to business processes
Everything here links back to the same verified catalogue. Pick your next stop.